secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001193125-25-193351
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks discontinues ZW171 Phase 1 after dose escalation; benefit-risk profile unfavorable
--------------------------------------------------------------------------------

- Decision based on completed dose escalation in ovarian and NSCLC patients; MTD established but benefit-risk not supportive.
- Dose-limiting toxicities consistent with mesothelin-related on-target off-tumor toxicity; CRS was well-managed.
- Ongoing participants may continue at investigator discretion; discontinued patients remain in safety follow-up.
- Pipeline continues: ZW191 Phase 1 ongoing, ZW251 Phase 1 expected 2025, ZW209 IND filing planned H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525193351/0001193125-25-193351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525193351/d88452d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-193351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer